Compare BAFN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | PMN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 34.6M |
| IPO Year | 2021 | 2022 |
| Metric | BAFN | PMN |
|---|---|---|
| Price | $6.53 | $24.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 13.7K | ★ 190.9K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 133.93 | 110.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.72 | $0.29 |
| 52 Week High | $19.15 | $21.83 |
| Indicator | BAFN | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 87.14 |
| Support Level | $6.31 | $0.43 |
| Resistance Level | $8.26 | N/A |
| Average True Range (ATR) | 0.45 | 1.71 |
| MACD | -0.01 | 0.64 |
| Stochastic Oscillator | 0.53 | 98.91 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.